Table 1.
Patient Clinical Information.
| Patient and Tumor Characteristics | pCR (n = 21) | Non-pCR (n = 71) | |
|---|---|---|---|
| Age (median, years) | 55 | 50 | |
| Sex | Male | 1 | 1 |
| Female | 20 | 70 | |
| Menopause status | Premenopausal | 5 | 39 |
| Postmenopausal | 13 | 26 | |
| Perimenopasual | 1 | 2 | |
| N/A | 2 | 4 | |
| Pretreatment tumor size (largest diameter, cm) | 3.53 ± 1.75 | 5.46 ± 2.53 | |
| Posttreatment tumor size (largest diameter, cm) | N/A | 2.97 ± 3.18 | |
| Molecular subtype | Luminal | 9 (10%) | 52 (57%) |
| Basal-like | 7 (8%) | 14 (15%) | |
| HER-2 positive | 5 (5%) | 5 (5%) | |
| Stage | |||
| Primary tumor (T) | T1 | 1 (1%) | 1 (1%) |
| T2 | 8 (9%) | 21 (23%) | |
| T3 | 3 (3%) | 20 (22%) | |
| T4 | 0 | 1 (1%) | |
| T4b | 0 | 1 (1%) | |
| T4d | 0 | 2 (2%) | |
| Unavailable | 9 (10%) | 25 (27%) | |
| Node involvement (N) | N0 | 2 (2%) | 13 (14%) |
| N1 | 9 (10%) | 29 (32%) | |
| N2 | 0 | 3 (3%) | |
| N3 | 1 (1%) | 0 | |
| Unavailable | 9 (10%) | 26 (28%) | |
| Chemotherapy regimen | |||
| FEC-D (fluorouracil, epirubicin and cyclophosphamide followed by docetaxel) | 6 (7%) | 33 (36%) | |
| AC-T (doxorubicin (Adriamycin) and cyclophosphamide followed by paclitaxel (Taxol)) | 11 (12%) | 34 (37%) | |
| TC (paclitaxel (Taxol) and cyclophosphamide) | 1 (1%) | 4 (4%) | |
| AC (doxorubicin (Adriamycin) and cyclophosphamide) | 1 (1%) | 0 | |
| AC-D (doxorubicin (Adriamycin) and cyclophosphamide followed by docetaxel) | 1 (1%) | 0 | |
| Carboplatin and paclitaxel (Taxol) followed by doxorubicin (Adriamycin) and cyclophosphamide | 1 (1%) | 0 | |
Patient demographics, tumor characteristics, and treatment details prior to and after NAC. Patients, whose data are presented in this table, were not consecutively recruited.